Prophylactic use of tranexamic acid to reduces blood loss and transfusion requirements in caesarean section

Urmila Sunda, Priyanka Bhadana


Background: Postpartum haemorrhage (PPH) is most dreaded complication which occurs worldwide, more prevalent in developing countries after both vaginal and caesarean delivery. Prophylactic administration of a uterotonics immediately after delivery is the only procedure that has been proved to reduce rates of postpartum haemorrhage. Tranexamic acid, an antifibrinolytic is recommended by WHO for management of PPH, its role to reduce blood loss in caesarean section as a prophylactic agent is not well studied.

Methods: This study was conducted in a tertiary care hospital at New Delhi total 100 pregnant women with age ≥18 and <35 years and singleton alive fetus who underwent caesarean section were included for this study.  Study population was divided in two group. Women assigned to the study group received 1 gm tranexamic acid slowly intravenously over 10 minutes after delivery of the baby as per existing unit protocol. Those women who received tranexamic acid was compared with other group who did not received tranexamic acid. The primary outcomes were mean blood loss (ml) and mean fall in hemoglobin level within 48 hours after surgery.

Results: Amount of blood loss was significantly low (mean 369 ml) in tranexamic acid group as compared to control group (488 ml), the difference was statistically significant (p value 0.001).  Mean fall in haemoglobin level was also low (1.17 mg/dl) in group who received tranexamic acid as compared to control group (1.87 mg/dl), the difference was statistically significant (p value 0.001). Postpartum hemorrhage (blood loss more than 1000 ml) was observed in 1 patient in control group and no case of PPH was observed in study group.

Conclusions: Tranexamic acid administration prior to caesarean section was effective in reducing the blood loss intra and postoperative period, without any immediate maternal and neonatal adverse events as well as reduces the need of blood transfusion.


Caesarean section, Postpartum haemorrhage, Tranexamic acid

Full Text:



Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323-333.

Knight M, Callaghan WM, Berg C, Alexander S, Bouvier-Colle MH, Ford JB, et al. Trends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Postpartum Hemorrhage Collaborative Group. BMC Preg Childbirth. 2009;9:55.

WHO recommendations for the prevention and treatment of postpartum haemorrhage. World Health Organization; Available at: Accessed on 12th April 2020.

Sebghati M, Chandraharan E. An update on the risk factors for and management of obstetric haemorrhage. Womens Health. 2017;13(2):34-40.

Begley CM, Gyte GML, Devane D, McGuire W, Weeks A. Active versus expectant management for women in the third stage of labour. Cochrane Database Syst Rev. 2011;(11):CD007412.

Wu G, Mazzitelli BA, Quek AJ, Veldman MJ, Conroy PJ, Caradoc-Davies TT, et al. Tranexamic acid is an active site inhibitor of urokinase plasminogen activator. Blood Adv. 2019;3(5):729-33.

Moiz B. A review of hemostasis in normal pregnancy and puerperium. Nat J Health Sci. 2017;2(3):123-7.

Sentilhes L, Winer N, Azria E, Sénat MV, Le Ray C, Vardon D, et al. Tranexamic acid for the prevention of blood loss after vaginal delivery. N Engl J Med. 2018;379(8):731-42.

Shakur H, Elbourne D, Gülmezoglu M, Alfirevic Z, Ronsmans C, Allen E, et al. The woman trial (World maternal antifibrinolytic trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo-controlled trial. Trials. 2010;11:40.

Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess Winch Engl. 2013;17(10):1-79.

WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage. World Health Organization. Available at: Accessed on 12th April 2020.

Lakshmi SD, Abraham R. Role of prophylactic tranexamic acid in reducing blood loss during elective caesarean section: a randomized controlled study. J Clin Diagn Res. 2016;10(12):QC17-21.

Levy JH, Dutton RP, Hemphill JC, Shander A, Cooper D, Paidas MJ, et al. Multidisciplinary approach to the challenge of hemostasis. Anesth Analg. 2010;110(2):354-64.

Gungorduk K, Yıldırım G, Asıcıoglu O, Gungorduk OC, Sudolmus S, Ark C. Efficacy of intravenous tranexamic acid in reducing blood loss after elective caesarean section: a prospective, randomized, double- blind, placebo-controlled study. Am J Perinatol. 2011;28:233-40.

Movafegh A, Eslamian L, Dorabadi A. Effect of intravenous tranexamic acid administration on blood loss during and after caesarean delivery. Int J Gynecol Obstet. 2011;115:224-6.

Shahid A, Khan A. Tranexamic acid in decreasing blood loss during and after caesarean section. J Coll Physicians Surg Pak. 2013;23:459-62.

Nath J. A study on use of tranexamic acid in reducing blood loss during lower segment caesarean section. Int J Sci Res. 2015;4:1236-8.

Novikova N, Hofmeyr GJ, Cluver C. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2015;(6):CD007872.

Sentilhes L, Daniel V, Darsonval A, Deruelle P, Vardon D, Perrotin F, et al. Study protocol. TRAAP-TRAnexamic acid for preventing postpartum hemorrhage after vaginal delivery: a multicentre randomized, double-blind, placebo-controlled trial. BMC Preg Childbirth. 2015;15(1):135.

Wang HY, Hong SK, Duan Y, Yin HM. Tranexamic acid and blood loss during and after caesarean section: a meta-analysis. J Perinatol. 2015;35(10):818-25.